Cyclone® 30XP
Connect to the future.
- PET Imaging
- SPECT Imaging
- Therapy
- 211At
- 201Tl
- 111In
- 68Ge
- 123I
- 64Cu
- 18F
- 124I
- 89Zr
- 13N
- 11C
- 15O
- The most flexible cyclotron
Cyclone® 30XP is a multi-particle variable energy cyclotron that accelerates protons (from 15 to 30 MeV), deuterons (from 8 to 15 MeV) and alphas (30 MeV).
- Complete solution for fast new development
Cyclone® 30XP comes equipped with a wide range of NIRTA® targets, empowering rapid development of new radioisotopes and delivering an accelerated path from concept to operation.
- Energy
From 15 to 30 MeV for Proton. From 8 to 15 MeV for Deuteron. 30 MeV for Alpha He++
- Cyclotron dimensions
2.7 x 3.9 m
- Target
High power solid, compact PET solid, liquid & gas
- Vault dimensions
8 x 7.5 x 4 m
- Exit ports
2 exits
- Beam lines
Up to 4 beam lines and external switching magnet
- Production power
400 µA (H-), 50 µA (D-), 50 µA (He2+)
- High flexibility
With proton (400 µA), deuteron (50 µA) and alpha (50 µAe), it is the perfect tool to combine the field of diagnosis and therapy as well as research and development works.
- Extensive PET & SPECT production possibilities
Energy range from 15 to 30 MeV gives the flexibility to produce a wide range of radioisotopes, including 18F, 64Cu, 89Zr, 68Ge, 123I, 111In, 201Tl and 211At from external alpha beam.
- Complete solution
IBA is the only supplier that offers you a complete solution & integration of beam transport lines, targetry, chemistry and laboratory equipment for high energy cyclotron.
- Ready when you are
IBA promises that your cyclotron is available when you are ready with your building.
Interested to learn more about the Cyclone® 30XP?
Download product information
Find out everything you need to know about the Cyclone® 30XP.
You don’t only have to take our word for it. Here is what others say about the Cyclone® 30XP.
This cyclotron will provide us with new radiopharmaceuticals and notably the alpha emitter At-211 for local distribution
“At CERAD (Center of Design and Synthesis of Radiopharmaceuticals for Molecular Targeting), the strategic research infrastructure in Poland, we are delighted to add the Cyclone® 30XP to reach our objectives.
This cyclotron will provide us with new radiopharmaceuticals and notably the alpha emitter At-211 for local distribution.”
IBA high-energy cyclotrons installed across the world
The IBA Cyclone® 30XP is a reference in terms of versability
“The IBA Cyclone® 30XP is a reference in terms of versability, with its capability of producing Proton and Deuteron beam from 15 to 30 MeV as well as 30 MeV Alpha particles. Its dedicated PET Beam Line can be equipped with up to five “low energy” targets, and its two dedicated SPECT Beam Lines can be equipped with a variety of high energy targets. This level of flexibility allows the user to produce a large range of radioisotopes, from staples such as F-18, to more exotic ones, namely At-211.”
- 12/12/2023
IBA pioneers theranostic advancements, empowering the market to produce Astatine-211Louvain-la-Neuve, Belgium, December 12, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and of radiopharmaceutical production solutions is pleased to announce the start of the installation of a Cyclone® 30XP in Poland. There are now three sites set to produce Astatine-211 (At-211) for oncology applications, reaffirming IBA’s leadership and innovation in the area of radiotheranostics.
The completion of the rigging in POLATOM on December 11th follows the successful commissioning of the first Cyclone® 30XP machine in Jülich, Germany, earlier this year. Furthermore, an IBA cyclotron Cyclone® 70XP, installed in France in 2008, has enabled multiple research programs already.
IBA and the three sites, ARRONAX (France), Forschungszentrum Jülich (Germany), and POLATOM (Poland), are active participants in COST Action 19114: A European Network Dedicated to Targeted Alpha Therapy (TAT) with At-211. This collaborative effort showcases a commitment to overcoming challenges and advancing targeted alpha therapy research.
Despite its scarcity, At-211, an alpha emitter, is used in clinical research for targeted alpha-therapies in the field of oncology to treat brain, thyroid, ovarian, breast, prostate cancer1. Beyond At-211, IBA is also pioneering novel accelerator applications for other theranostic isotopes.
“IBA is at the forefront of revolutionizing the radiotheranostics landscape by addressing critical market availability challenges of radiopharmaceuticals such as Astatine-211 and Actinium-225. The company's groundbreaking efforts focus on 'unlocking' alpha emitters for theranostic applications,” said Bruno Scutnaire, President of IBA RadioPharma Solutions.
“The GIP Arronax (France) was the first institution to use the IBA multiparticle cyclotron. Since its installation in 2008, the cyclotron has enabled commercial activities, but also multiple research programs,” said Dr. Ferid Haddad, Managing Director of the GIP Arronax. “With the unique alpha beam capacity, the production of At-211 has enabled the institution and its partners to develop a better understanding of the At-211 chemistry, to develop radiolabeling methods and to conduct preclinical studies in order to prepare for clinical trials on new radiopharmaceutical for alpha-therapy,” he added.
“As a leading research institution and in our role as an international partner in the field of nuclear medicine, we are delighted to announce the successful operation of the Cyclone® 30XP multiparticles cyclotron,” commented Professor Dr. Bernd Neumaier, Director of Institute of Neuroscience and Medicine (INM-5). “With our recent milestone of successfully directing an alpha beam onto a Bi-target, we are poised to advance our efforts in the development of At-211. This achievement solidifies the position of the INM-5 of the Forschungszentrum Jülich as a key provider of this promising alpha-emitting isotope for cancer therapies” he added.
“At CERAD (Center of Design and Synthesis of Radiopharmaceuticals for Molecular Targeting), the strategic research infrastructure in Poland, we are delighted to add the Cyclone® 30XP to reach our objectives,” said Prof. Renata Mikolajczak, research and cooperation manager of Radioisotope Centre POLATOM, National Center for Nuclear Research. “This cyclotron will provide us with new radiopharmaceuticals and notably the alpha emitter At-211 for local distribution”, she added.
*Astatine-211 based radionuclide therapy: Current clinical trial landscape - link
- 13/12/2023
- POLATOM
Successful rigging of IBA's Cyclone® 30XP at POLATOM, PolandWe are happy to announce the successful rigging of our Cyclone® 30XP cyclotron at POLATOM that marks a significant milestone for the CERAD project in Poland.
This cyclotron will provide POLATOM with new radiopharmaceuticals and notably the alpha emitter Astatine-211 (At-211) used in clinical research for targeted alpha-therapies to treat brain, thyroid, ovarian, breast and prostate cancer.
Congratulations to POLATOM for this important achievement !
- 19/12/2025
IBA acquires ORA expanding its strategic leadership in Nuclear MedicineLouvain-la-Neuve, Belgium, December 19, 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium.
This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient therapy.
The combination of IBA cyclotron leadership with ORA’s cutting-edge technology provides one of the most competitive integrated solutions for hospitals and global radiopharmacy networks looking for high productivity and access to labelling of advanced radioisotopes.
This acquisition complements IBA’s existing nuclear medicine strategic initiatives including the co-founding of PanTera for the production of Ac-225, and the shaping of the Accelerate.EU program, as well as the ongoing collaboration with Framatome to explore opportunities in the production of At-211. It is an additional step for IBA on its journey to bring innovation in care to patients and to accelerate the translation of innovative nuclear medicine solutions from bench to bedside.
The transaction, for a total consideration of € 15-20 million on a cash-free, debt-free basis, is immediately accretive to IBA Technologies’ revenue and EBITDA and is expected to generate revenue synergies. Financed through IBA’s own funds and existing credit facilities, the acquisition will not have material impact on IBA’s 2025 financial guidance or mid-term outlook.
“Joining forces with IBA opens exciting opportunities to scale our NEPTIS® technology and accelerate innovation in radiochemistry.” said Vincent Tadino, Founder and Chief Executive Officer of ORA. “Together, we will continue to push the boundaries of PET and therapeutic radiochemistry, ensuring our customers have access to the most advanced and reliable solutions for radiopharmaceutical production.”
“ORA’s acquisition accelerates our mission to deliver integrated solutions from isotope production to patient-ready therapies, making advanced cancer treatments and diagnostics more accessible worldwide” stated Charles Kumps, President of IBA RadioPharma Solutions, “I am particularly excited that Vincent will continue to lead as Chief Technology Officer of ORA, bringing his vision and deep expertise to our joint efforts.”